These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

896 related articles for article (PubMed ID: 32941929)

  • 21. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
    Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
    Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies.
    Chen Y; Fu AKY; Ip NY
    Pharmacol Ther; 2019 Mar; 195():186-198. PubMed ID: 30439458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.
    Umeda T; Ono K; Sakai A; Yamashita M; Mizuguchi M; Klein WL; Yamada M; Mori H; Tomiyama T
    Brain; 2016 May; 139(Pt 5):1568-86. PubMed ID: 27020329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review on Alzheimer's disease pathophysiology and its management: an update.
    Kumar A; Singh A; Ekavali
    Pharmacol Rep; 2015 Apr; 67(2):195-203. PubMed ID: 25712639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
    Pinheiro L; Faustino C
    Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent Advances in the Treatment and Management of Alzheimer's Disease: A Precision Medicine Perspective.
    Shukla D; Suryavanshi A; Bharti SK; Asati V; Mahapatra DK
    Curr Top Med Chem; 2024; 24(19):1699-1737. PubMed ID: 38566385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging amyloid and tau targeting treatments for Alzheimer's disease.
    Khan A; Corbett A; Ballard C
    Expert Rev Neurother; 2017 Jul; 17(7):697-711. PubMed ID: 28490214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.
    Castillo-Carranza DL; Guerrero-Muñoz MJ; Sengupta U; Hernandez C; Barrett AD; Dineley K; Kayed R
    J Neurosci; 2015 Mar; 35(12):4857-68. PubMed ID: 25810517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond.
    Song C; Shi J; Zhang P; Zhang Y; Xu J; Zhao L; Zhang R; Wang H; Chen H
    Transl Neurodegener; 2022 Mar; 11(1):18. PubMed ID: 35300725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tau immunotherapies for Alzheimer's disease.
    Hoskin JL; Sabbagh MN; Al-Hasan Y; Decourt B
    Expert Opin Investig Drugs; 2019 Jun; 28(6):545-554. PubMed ID: 31094578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of tau protein in Alzheimer's disease: The prime pathological player.
    Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B
    Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.
    Hampel H; Schneider LS; Giacobini E; Kivipelto M; Sindi S; Dubois B; Broich K; Nisticò R; Aisen PS; Lista S
    Expert Rev Neurother; 2015 Jan; 15(1):83-105. PubMed ID: 25537424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AADvac1, an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development.
    Novak P; Zilka N; Zilkova M; Kovacech B; Skrabana R; Ondrus M; Fialova L; Kontsekova E; Otto M; Novak M
    J Prev Alzheimers Dis; 2019; 6(1):63-69. PubMed ID: 30569088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Passive immunotherapy for Alzheimer's disease.
    Guo X; Yan L; Zhang D; Zhao Y
    Ageing Res Rev; 2024 Feb; 94():102192. PubMed ID: 38219962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer's disease.
    Zhang F; Zhong RJ; Cheng C; Li S; Le WD
    Acta Pharmacol Sin; 2021 Sep; 42(9):1382-1389. PubMed ID: 33268824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of tau-directed small molecule modulators for Alzheimer's disease: a recent patent review (2014-2018).
    Lee HE; Lim D; Lee JY; Lim SM; Pae AN
    Pharm Pat Anal; 2019 Jan; 8(1):15-39. PubMed ID: 30870110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies.
    Sigurdsson EM
    J Alzheimers Dis; 2024; 101(s1):S129-S140. PubMed ID: 38427486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct Interaction between the β-Amyloid Core and Tau Facilitates Cross-Seeding: A Novel Target for Therapeutic Intervention.
    Tripathi T; Khan H
    Biochemistry; 2020 Feb; 59(4):341-342. PubMed ID: 31944100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.